486 related articles for article (PubMed ID: 11917201)
1. The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status.
Orem C; Orem A; Uydu HA; Celik S; Erdöl C; Kural BV
Coron Artery Dis; 2002 Feb; 13(1):65-71. PubMed ID: 11917201
[TBL] [Abstract][Full Text] [Related]
2. The evaluation of autoantibodies against oxidatively modified low-density lipoprotein (LDL), susceptibility of LDL to oxidation, serum lipids and lipid hydroperoxide levels, total antioxidant status, antioxidant enzyme activities, and endothelial dysfunction in patients with Behçet's disease.
Orem A; Yandi YE; Vanizor B; Cimşit G; Uydu HA; Malkoç M
Clin Biochem; 2002 May; 35(3):217-24. PubMed ID: 12074830
[TBL] [Abstract][Full Text] [Related]
3. The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia.
Kural BV; Orem C; Uydu HA; Alver A; Orem A
Coron Artery Dis; 2004 Aug; 15(5):277-83. PubMed ID: 15238825
[TBL] [Abstract][Full Text] [Related]
4. The significance of autoantibodies against oxidatively modified low-density lipoprotein (LDL) in patients with psoriasis.
Orem A; Cimşit G; Değer O; Orem C; Vanizor B
Clin Chim Acta; 1999 Jun; 284(1):81-8. PubMed ID: 10437645
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis.
Vanizor Kural B; Orem A; Cimşit G; Yandi YE; Calapoglu M
Clin Chim Acta; 2003 Feb; 328(1-2):71-82. PubMed ID: 12559600
[TBL] [Abstract][Full Text] [Related]
6. Autoantibodies against oxidized LDL and serum total antioxidant status in active cyclists and ex-cyclists.
García-Unzueta MT; Gutiérrez-Sánchez JB; de Mier I; Amado JA; Berrazueta JR
Horm Metab Res; 2003 Sep; 35(9):541-5. PubMed ID: 14517771
[TBL] [Abstract][Full Text] [Related]
7. Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.
Navarro JF; Mora C; Muros M; García-Idoate G
Nephron Clin Pract; 2003; 95(4):c128-35. PubMed ID: 14694274
[TBL] [Abstract][Full Text] [Related]
8. Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia.
van Tits LJ; Smilde TJ; van Wissen S; de Graaf J; Kastelein JJ; Stalenhoef AF
J Investig Med; 2004 Apr; 52(3):177-84. PubMed ID: 15222407
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes.
Fuhrman B; Koren L; Volkova N; Keidar S; Hayek T; Aviram M
Atherosclerosis; 2002 Sep; 164(1):179-85. PubMed ID: 12119208
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of low-density lipoprotein oxidation by oral herbal mixtures Maharishi Amrit Kalash-4 and Maharishi Amrit Kalash-5 in hyperlipidemic patients.
Sundaram V; Hanna AN; Lubow GP; Koneru L; Falko JM; Sharma HM
Am J Med Sci; 1997 Nov; 314(5):303-10. PubMed ID: 9365332
[TBL] [Abstract][Full Text] [Related]
11. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.
Pontrelli L; Parris W; Adeli K; Cheung RC
Metabolism; 2002 Mar; 51(3):334-42. PubMed ID: 11887170
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: a randomized, double-blind, placebo-controlled study.
Yoshida H; Ishikawa T; Ayaori M; Shige H; Ito T; Suzukawa M; Nakamura H
Atherosclerosis; 1998 Jul; 139(1):179-87. PubMed ID: 9699906
[TBL] [Abstract][Full Text] [Related]
13. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
Guerin M; Lassel TS; Le Goff W; Farnier M; Chapman MJ
Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):189-97. PubMed ID: 10634817
[TBL] [Abstract][Full Text] [Related]
14. Plasma fibronectin level and its relationships with lipids, lipoproteins and C-reactive protein in patients with dyslipidaemia during lipid-lowering therapy.
Orem C; Orem A; Calapoğlu M; Baykan M; Uydu HA; Erdöl C
Acta Cardiol; 2002 Dec; 57(6):421-5. PubMed ID: 12542120
[TBL] [Abstract][Full Text] [Related]
15. The effects of atorvastatin on oxidative stress in L-NAME-treated rats.
Sozer V; Uzun H; Gelisgen R; Kaya M; Kalayci R; Tabak O; Arican N; Konukoglu D
Scand J Clin Lab Invest; 2013 Oct; 73(7):591-7. PubMed ID: 24024670
[TBL] [Abstract][Full Text] [Related]
16. Autoantibodies against oxidized low-density lipoprotein (ox-LDL) and LDL oxidation status.
Brizzi P; Tonolo G; Bertrand G; Carusillo F; Severino C; Maioli M; Malaguarnera L; Musumeci S
Clin Chem Lab Med; 2004 Feb; 42(2):164-70. PubMed ID: 15061355
[TBL] [Abstract][Full Text] [Related]
17. Gemfibrozil decreases autoantibodies against oxidized low-density lipoprotein in men with combined hyperlipidaemia.
Hoogerbrugge N; Kerkhofs LG; Jansen H
J Intern Med; 1998 May; 243(5):355-9. PubMed ID: 9651557
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation.
Aviram M; Rosenblat M; Bisgaier CL; Newton RS
Atherosclerosis; 1998 Jun; 138(2):271-80. PubMed ID: 9690910
[TBL] [Abstract][Full Text] [Related]
19. [Atorvastatin and oxidized low density lipoprotein antibody. Relationship to age].
Sánchez Muñoz-Torrero JF; Crespo L; Fernández Pereira L; Pereira G; Cámara C; Costo A
Med Clin (Barc); 2011 Feb; 136(5):199-201. PubMed ID: 21145076
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
